Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells

As cyclin-dependent kinases (CDKs) regulate cell cycle progression and RNA transcription, CDKs are attractive targets for creating cancer cell treatments. In this study we investigated the effects of the small molecular agent NU6140 (inhibits CDK2 and cyclin A interaction) on human embryonic stem (h...

Full description

Saved in:
Bibliographic Details
Main Authors: Ade Kallas, Martin Pook, Annika Trei, Toivo Maimets
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:International Journal of Cell Biology
Online Access:http://dx.doi.org/10.1155/2014/280638
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849308637069049856
author Ade Kallas
Martin Pook
Annika Trei
Toivo Maimets
author_facet Ade Kallas
Martin Pook
Annika Trei
Toivo Maimets
author_sort Ade Kallas
collection DOAJ
description As cyclin-dependent kinases (CDKs) regulate cell cycle progression and RNA transcription, CDKs are attractive targets for creating cancer cell treatments. In this study we investigated the effects of the small molecular agent NU6140 (inhibits CDK2 and cyclin A interaction) on human embryonic stem (hES) cells and embryonal carcinoma-derived (hEC) cells via the expression of transcription factors responsible for pluripotency. A multiparameter flow cytometric method was used to follow changes in the expression of NANOG, OCT4, and SOX2 together in single cells. Both hES and hEC cells responded to NU6140 treatment by induced apoptosis and a decreased expression of NANOG, OCT4, and SOX2 in surviving cells. A higher sensitivity to NU6140 application in hES than hEC cells was detected. NU6140 treatment arrested hES and hEC cells in the G2 phase and inhibited entry into the M phase as evidenced by no significant increase in histone 3 phosphorylation. When embryoid bodies (EBs) formed from NU6104 treated hES cells were compared to EBs from untreated hES cells differences in ectodermal, endodermal, and mesodermal lineages were found. The results of this study highlight the importance of CDK2 activity in maintaining pluripotency of hES and hEC cells and in differentiation of hES cells.
format Article
id doaj-art-0e5362c80e754ff2ab7b495fe0d68bd1
institution Kabale University
issn 1687-8876
1687-8884
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series International Journal of Cell Biology
spelling doaj-art-0e5362c80e754ff2ab7b495fe0d68bd12025-08-20T03:54:24ZengWileyInternational Journal of Cell Biology1687-88761687-88842014-01-01201410.1155/2014/280638280638Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 CellsAde Kallas0Martin Pook1Annika Trei2Toivo Maimets3Institute of Molecular and Cell Biology, University of Tartu, Riia 23, 51010 Tartu, EstoniaInstitute of Molecular and Cell Biology, University of Tartu, Riia 23, 51010 Tartu, EstoniaInstitute of Molecular and Cell Biology, University of Tartu, Riia 23, 51010 Tartu, EstoniaInstitute of Molecular and Cell Biology, University of Tartu, Riia 23, 51010 Tartu, EstoniaAs cyclin-dependent kinases (CDKs) regulate cell cycle progression and RNA transcription, CDKs are attractive targets for creating cancer cell treatments. In this study we investigated the effects of the small molecular agent NU6140 (inhibits CDK2 and cyclin A interaction) on human embryonic stem (hES) cells and embryonal carcinoma-derived (hEC) cells via the expression of transcription factors responsible for pluripotency. A multiparameter flow cytometric method was used to follow changes in the expression of NANOG, OCT4, and SOX2 together in single cells. Both hES and hEC cells responded to NU6140 treatment by induced apoptosis and a decreased expression of NANOG, OCT4, and SOX2 in surviving cells. A higher sensitivity to NU6140 application in hES than hEC cells was detected. NU6140 treatment arrested hES and hEC cells in the G2 phase and inhibited entry into the M phase as evidenced by no significant increase in histone 3 phosphorylation. When embryoid bodies (EBs) formed from NU6104 treated hES cells were compared to EBs from untreated hES cells differences in ectodermal, endodermal, and mesodermal lineages were found. The results of this study highlight the importance of CDK2 activity in maintaining pluripotency of hES and hEC cells and in differentiation of hES cells.http://dx.doi.org/10.1155/2014/280638
spellingShingle Ade Kallas
Martin Pook
Annika Trei
Toivo Maimets
Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells
International Journal of Cell Biology
title Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells
title_full Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells
title_fullStr Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells
title_full_unstemmed Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells
title_short Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells
title_sort assessment of the potential of cdk2 inhibitor nu6140 to influence the expression of pluripotency markers nanog oct4 and sox2 in 2102ep and h9 cells
url http://dx.doi.org/10.1155/2014/280638
work_keys_str_mv AT adekallas assessmentofthepotentialofcdk2inhibitornu6140toinfluencetheexpressionofpluripotencymarkersnanogoct4andsox2in2102epandh9cells
AT martinpook assessmentofthepotentialofcdk2inhibitornu6140toinfluencetheexpressionofpluripotencymarkersnanogoct4andsox2in2102epandh9cells
AT annikatrei assessmentofthepotentialofcdk2inhibitornu6140toinfluencetheexpressionofpluripotencymarkersnanogoct4andsox2in2102epandh9cells
AT toivomaimets assessmentofthepotentialofcdk2inhibitornu6140toinfluencetheexpressionofpluripotencymarkersnanogoct4andsox2in2102epandh9cells